Plaintiffs in consolidated Risperdal lawsuits now pending in Pennsylvania have argued that a New Jersey statute barring punitive damages in lawsuits brought involving FDA-approved drugs does not apply when the injuries alleged result from off-label or uses unapproved by the FDA. Janssen Pharmaceuticals, Inc., the division of Johnson & Johnson that manufactured and distributed Risperdal, had argued that insofar as the antipsychotic medication had been approved by the FDA, the plaintiffs in hundreds of lawsuits coordinated in Pennsylvania could not prevail... Read More

Plaintiffs in consolidated Risperdal lawsuits now pending in Pennsylvania have argued that a New Jersey statute barring punitive damages in lawsuits brought involving FDA-approved drugs does not apply when the injuries alleged result from off-label or uses unapproved by the FDA. Janssen Pharmaceuticals, Inc., the division of Johnson & Johnson that manufactured and distributed Risperdal, had argued that insofar as the antipsychotic medication had been approved by the FDA, the plaintiffs in hundreds of lawsuits coordinated in Pennsylvania could not prevail... Read More

On March 20, 2014, the Arkansas Supreme Court overturned a trial court award of $1.2 billion to the State of Arkansas against Johnson & Johnson, and its Janssen Pharmaceuticals, Inc. division based on the company's marketing of the antipsychotic frog Risperdal.  This Arkansas lawsuit had been brought by the Arkansas Attorney General and relied on a provision of Arkansas state law governing Medicaid fraud as a basis to challenge the marketing of Risperdal in Arkansas which allegedly included misleading claims... Read More